Literature DB >> 1441021

Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors.

D Sidransky1, E Messing.   

Abstract

Transitional-cell carcinoma of the bladder is believed to arise through a series of genetic changes affecting cell growth and proliferation. Two basic types of such genes have been described: protooncogenes and tumor suppressor genes. The former have not been studied extensively in bladder cancer, although there is evidence that c-erb B-2/neu is overexpressed. Loss of specific chromosomal regions, which is common in bladder tumors, may inactivate tumor suppressor genes, of which p53 has received the most attention. Work also has been done on epidermal growth factor and its receptor, yielding evidence that malignant and normal urothelium have different sensitivities to its action. Although several advances must be made before genetic changes come to the clinical forefront, the information now being gained with such speed holds considerable promise for diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1441021

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  10 in total

1.  Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.

Authors:  M Loda; P Capodieci; R Mishra; H Yao; C Corless; W Grigioni; Y Wang; C Magi-Galluzzi; P J Stork
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients.

Authors:  Arisan Serdar; Caskurlu Turhan; Guney Soner; Sonmez Nurettin Cem; Keles Bayram; Buyuktuncer Elif Damla; Ergenekon Erbil
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

4.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.

Authors:  I A Sokolova; K C Halling; R B Jenkins; H M Burkhardt; R G Meyer; S A Seelig; W King
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

5.  Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.

Authors:  H Bialkowska-Hobrzanska; L Bowles; B Bukala; M G Joseph; R Fletcher; H Razvi
Journal:  Mol Diagn       Date:  2000-12

6.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

7.  Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder.

Authors:  M Li; Z F Zhang; V E Reuter; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

Review 8.  Bladder cancer: the molecular progression to invasive disease.

Authors:  A R Simoneau; P A Jones
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

9.  Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.

Authors:  Xuan Liu; Hans-Peter Sinn; Hans Ulrich Ulmer; Rodney J Scott; Ute Hamann
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

10.  Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients.

Authors:  J Harney; D M Murphy; M Jones; C Mothersill
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.